SCHEMBL12296115

SCHEMBL12296115

COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CCC(O)C2)cc1O

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 1/20 0.84
KCNA5 P22460 6/20 0.83
SCN5A Q14524 6/20 0.83
KCND2 Q9NZV8 5/20 0.83
KCNH2 Q12809 1/20 0.83
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
TSHR P16473 1/20 0.41
NFKB1 P19838 1/20 0.41
LMNA P02545 2/20 0.41
MEN1 O00255 1/20 0.41
APEX1 P27695 1/20 0.41
KMT2A Q03164 1/20 0.41
TUBB4A P04350 2/20 0.40
TUBB P07437 2/20 0.40
TUBA3C P0DPH7 2/20 0.40
TUBA1B P68363 2/20 0.40
TUBA4A P68366 2/20 0.40
TUBB4B P68371 2/20 0.40
TUBB3 Q13509 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL410599 1.00 SLC6A4 (0.84) SLC6A4KCNA5SCN5AKCND2KCNH2
SCHEMBL12327948 1.00 SLC6A4 (0.84) SLC6A4KCNA5SCN5AKCND2KCNH2
Hydrochloric Acid SCHEMBL439835 0.99 KCNA5 (0.85) SLC6A4KCNA5SCN5AKCND2KCNH2
SCHEMBL410072 0.92 SLC6A4 (0.84) SLC6A4KCNA5SCN5AKCND2KCNH2
SCHEMBL13097960 0.92 SLC6A4 (0.84) SLC6A4KCNA5SCN5AKCND2KCNH2
SCHEMBL12327983 0.92 SLC6A4 (0.84) SLC6A4KCNA5SCN5AKCND2KCNH2
SCHEMBL12122779 0.92 SLC6A4 (0.84) SLC6A4KCNA5SCN5AKCND2KCNH2
SCHEMBL14390503 0.92 SLC6A4 (0.84) SLC6A4KCNA5SCN5AKCND2KCNH2
SCHEMBL14851637 0.92 SLC6A4 (0.84) SLC6A4KCNA5SCN5AKCND2KCNH2
SCHEMBL12296102 0.92 SLC6A4 (0.84) SLC6A4KCNA5SCN5AKCND2KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8022098-B2 Deuterated aminocyclohexyl ether compounds and processes for preparing same CARDIOME PHARMA CORP. (CA) 2011-09-20 US disclosed
US-20100152276-A1 DEUTERATED AMINOCYCLOHEXYL ETHER COMPOUNDS AND PROCESSES FOR PREPARING SAME CARDIOME PHARMA CORP. (CA) 2010-06-17 US disclosed
US-7705036-B2 Deuterated aminocyclohexyl ether compounds and processes for preparing same CARDIOME PHARMA CORP. (CA) 2010-04-27 US disclosed
US-20070088075-A1 Deuterated aminocyclohexyl ether compounds and processes for preparing same CARDIOME PHARMA CORP. (CA) 2007-04-19 US disclosed
US-20070088075-A1 Deuterated aminocyclohexyl ether compounds and processes for preparing same CARDIOME PHARMA CORP. (CA) 2007-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070088075-A1 Deuterated aminocyclohexyl ether compounds and processes for preparing same DDC, HDHD5, DDT SLC6A4 2668/4885KCNA5 2363/4885SCN5A 4208/4885
US-20100152276-A1 DEUTERATED AMINOCYCLOHEXYL ETHER COMPOUNDS AND PROCESSES FOR PREPARING SAME DDC, HDHD5, DDT SLC6A4 2668/4885KCNA5 2363/4885SCN5A 4208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.